Cytoreductive radical prostatectomy (cRP) in the management of patients with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC).

被引：0
|
作者：
Heidenreich, Axel
Rieger, Constantin
Kastner, Lucas
Seelemeyer, Felix
Pfister, David
机构：
[1] Univ Hosp Cologne, Dept Urol, Cologne, Germany
[2] Univ Clin Cologne, Dept Urol, Cologne, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
161
引用
收藏
页数：1
相关论文
共 50 条
  • [31] PSMA PET/CT SUVmax as a prognostic biomarker in patients with metachronous metastatic hormone-sensitive prostate cancer (mHSPC)
    Henriquez, Ivan
    Malave, Barbara
    Campos, Fernando Lopez
    Hidalgo, Elena Centelles
    Muelas, Rodrigo
    Ferrer, Carlos
    Munoz-Rodriguez, Jesus
    Villamon, Agustina Mendez
    Pascual, Maria Cerrolaza
    Badia, Joan
    Fuertes, Jordi
    Hinojosa-Salas, Percy
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2025, 27 (02): : 706 - 715
  • [32] Current treatment options for newly diagnosed metastatic hormone-sensitive prostate cancer-a narrative review
    Ong, Sean
    O'Brien, Jonathan
    Medhurst, Elizabeth
    Lawrentschuk, Nathan
    Murphy, Declan
    Azad, Arun
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2021, 10 (10) : 3918 - 3930
  • [33] Feasibility of cotargeting cell cycle and androgen signaling in metastatic hormone-sensitive prostate cancer (mHSPC).
    Palmbos, Phillip Lee
    Tomlins, Scott A.
    Agarwal, Neeraj
    Twardowski, Przemyslaw
    Morgans, Alicia Katherine
    Kelly, William Kevin
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [34] Efficacy and tolerability of docetaxel chemotherapy in 'real-world' patients with metastatic hormone-sensitive prostate cancer (mHSPC)
    Maw, May Tun Hla
    Malik, Laeeq
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 127 - 127
  • [35] Prostatectomy in Patients with Oligometastatic Hormone-sensitive Prostate Cancer? Not Yet
    Blanchard, Pierre
    Vickers, Andrew J.
    EUROPEAN UROLOGY ONCOLOGY, 2022, 5 (05): : 526 - 527
  • [36] ARASENS: A phase 3 trial of darolutamide in males with metastatic hormone-sensitive prostate cancer (mHSPC)
    Tombal, B.
    Saad, F.
    Hussain, M.
    Sternberg, C. N.
    Fizazi, K.
    Crawford, E. D.
    Yamada, K.
    Kappeler, C.
    Kuss, I.
    Smith, M. R.
    ANNALS OF ONCOLOGY, 2017, 28
  • [37] Clinical outcomes in stratification subgroups in the ARASENS study in metastatic hormone-sensitive prostate cancer (mHSPC)
    Parnis, F.
    Tombal, B.
    Hussain, M.
    Saad, F.
    Fizazi, K.
    Sternberg, C. N.
    Crawford, E. D.
    Kopyltsov, E.
    Kalebasty, A. Rezazadeh
    Alekseev, B. Y.
    Montesa Pino, A.
    Ye, D.
    Melo Cruz, F. J. S.
    Tammela, T.
    Suzuki, H.
    Joensuu, H.
    Thiele, S.
    Li, R.
    Kuss, I.
    Smith, M.
    ANNALS OF ONCOLOGY, 2022, 33 : S1501 - S1502
  • [38] Optimal Pharmacotherapeutic Management of Hormone-Sensitive Metastatic Prostate Cancer
    Ajjai Alva
    Maha Hussain
    Drugs, 2013, 73 : 1517 - 1524
  • [39] Clinical Significance of Mesenchymal Circulating Tumor Cells in Patients With Oligometastatic Hormone-Sensitive Prostate Cancer Who Underwent Cytoreductive Radical Prostatectomy
    Yang, Guanjie
    Xie, Jun
    Zhang, Shun
    Gu, Wenyu
    Yuan, Jing
    Wang, Ruiliang
    Guo, Changcheng
    Ye, Lin
    Peng, Bo
    Yao, Xudong
    Yang, Bin
    FRONTIERS IN ONCOLOGY, 2022, 11
  • [40] Optimal Pharmacotherapeutic Management of Hormone-Sensitive Metastatic Prostate Cancer
    Alva, Ajjai
    Hussain, Maha
    DRUGS, 2013, 73 (14) : 1517 - 1524
12345